Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287521 · ClinicalTrials.gov registry record · Phase 2
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00287521 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 87 participants.
The verdict
NCT00287521, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG AL-37807 Ophthalmic Suspension, 1.0%
- DRUG Latanoprost, 0.005% (Xalatan)
- OTHER AL-37807 Vehicle
- DRUG Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287521
The ClinicalTrials.gov registry entry for NCT00287521 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AL-37807 Ophthalmic Suspension, 1.0% is the first listed.
NCT00287521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287521 about?
NCT00287521 is a clinical study titled "A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00287521?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2005-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00287521?
The interventions under investigation include: AL-37807 Ophthalmic Suspension, 1.0% (DRUG), Latanoprost, 0.005% (Xalatan) (DRUG), AL-37807 Vehicle (OTHER), Timolol Maleate Ophthalmic Gel Forming Solution, 0.5% (DRUG).
Who is sponsoring clinical trial NCT00287521?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.